Premium
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma
Author(s) -
Biran Noa,
Gourna Paleoudis Elli,
Feinman Rena,
Vesole David H.,
Zenreich Joshua,
Wang Shuqi,
Ahn Jaeil,
Bansal Meena,
Rowley Scott,
Donato Michele,
Pecora Andrew L.,
Richter Joshua,
Anand Palka,
McBride Laura,
Ivanovski Kristin,
Korngold Robert,
Siegel David S.
Publication year - 2021
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.26333
Subject(s) - lenalidomide , pembrolizumab , medicine , multiple myeloma , autologous stem cell transplantation , oncology , dexamethasone , minimal residual disease , bortezomib , immunology , immunotherapy , bone marrow , cancer